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Abstract
Background: Barrett’s esophagus (BE) occurs as consequence of reflux and is a risk factor for esophageal adenocarcinoma.
The current ‘‘gold-standard’’ for diagnosing BE is endoscopy which remains prohibitively expensive and impractical as a
population screening tool. We aimed to develop a pre-screening tool to aid decision making for diagnostic referrals.
Methodology/Principal Findings: A prospective (training) cohort of 1603 patients attending for endoscopy was used for
identification of risk factors to develop a risk prediction model. Factors associated with BE in the univariate analysis were
selected to develop prediction models that were validated in an independent, external cohort of 477 non-BE patients
referred for endoscopy with symptoms of reflux or dyspepsia. Two prediction models were developed separately for
columnar lined epithelium (CLE) of any length and using a stricter definition of intestinal metaplasia (IM) with segments
$2 cm with areas under the ROC curves (AUC) of 0.72 (95%CI: 0.67–0.77) and 0.81 (95%CI: 0.76–0.86), respectively. The two
prediction models included demographics (age, sex), symptoms (heartburn, acid reflux, chest pain, abdominal pain) and
medication for ‘‘stomach’’ symptoms. These two models were validated in the independent cohort with AUCs of 0.61
(95%CI: 0.54–0.68) and 0.64 (95%CI: 0.52–0.77) for CLE and IM$2 cm, respectively.
Conclusions: We have identified and validated two prediction models for CLE and IM$2 cm. Both models have fair
prediction accuracies and can select out around 20% of individuals unlikely to benefit from investigation for Barrett’s
esophagus. Such prediction models have the potential to generate useful cost-savings for BE screening among the
symptomatic population.
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Introduction
Barrett’s esophagus (BE) is a recognized pre-malignant condi-
tion in the pathogenesis of esophageal adenocarcinoma (EAC), a
malignancy whose incidence in the Western world has increased
six-fold over the past 30 years[1] and which carries a five-year
mortality in excess of 80% [2–4]. The squamous-to-columnar
metaplasia that is the hallmark of BE is thought to confer a
survival advantage on cells exposed to chronic gastro-esophageal
reflux [5], yet at the expense of an increased risk of progression to
esophageal adenocarcinoma [6]. In view of this malignant
potential, current endoscopic surveillance programs in patients
with known BE aim to identify patients with dysplasia at risk for
adenocarcinoma, yet prevalence data would suggest that the vast
majority of individuals with this condition remain undiagnosed
[7,8]. Several studies have reported risk factors associated with BE
including older age [9,10], male gender [9,11,12], Caucasian race
[13–15], gastro-esophageal reflux disease (GERD) [10,16,17],
smoking [18–20] and central obesity [21,22].
The current ‘‘gold-standard’’ for diagnosing BE is endoscopy,
which remains prohibitively expensive and impractical for
widespread use. In recent years, novel screening modalities,
including trans-nasal endoscopy and a non-endoscopic cell
collection device (Cytosponge) coupled with an immuno-marker
TFF3, have been suggested as alternatives to standard endoscopy
in the diagnosis of BE and have shown promise in early phase
studies [23–26]. The Cytosponge comprises a gelatin capsule
containing a compressed sponge material attached to a string. The
capsule is swallowed and after a few minutes the compressed
sponge is released from the capsule which when retrieved, by
pulling on the string, collects a large cell sample which can then be
processed for a BE specific biomarker TFF3. In a study conducted
in primary care the sensitivity and specificity of this approach was
90.0% and 93.5% for detection of intestinal metaplasia (IM) within
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segments of 2 cm or more [26]. Even if these methods prove highly
sensitive and specific for the detection of BE, however, it is unlikely
that one would want to screen the entire targeted population.
Regardless of the method employed, the ‘‘pre-selection’’ of
individuals for further investigation may be one way of maximiz-
ing the cost-effectiveness and detection rate of any putative
screening program. To achieve the goal of maximizing cost-
effectiveness, the ‘‘pre-selection’’ tool needs to have at least three
characteristics: 1) low cost; 2) be easy to administer; 3) excellent
sensitivity with fair specificity. Therefore, previous studies have
investigated the application of a prediction model based on a
questionnaire collecting clinical and demographic characteristics
to identify those individuals most likely to have BE, thus
warranting further endoscopic investigation [27–30]. However,
none of the studies have validated their model in another
independent prospective cohort study.
In view of recent advances in the development of novel non-
endoscopic BE screening modalities, we sought in this study to re-
appraise the feasibility of using a prediction model based on
demographic characteristics and GERD symptoms as a selection
tool to help clinicians decide who should be offered screening. To
this end, the primary aim of our prospective study was to
investigate the epidemiological factors and symptoms that may
predict the presence of BE in a large UK cohort of patients
attending upper GI endoscopy. The secondary aim was to develop
a pre-screening tool to exclude a subgroup of patients at extremely
low risk of having BE from requiring a screening intervention and
thus improve the cost-effectiveness of screening.
Materials and Methods
This study was approved by the local ethics committees of
Addenbrooke’s Hospital, Barking Havering and Redbridge
Hospitals, and University College London Hospitals. In the
validation cohort, after written informed consent had been
obtained, the participants completed a socio-demographic and
clinical questionnaire which had an assessment of symptoms, and
were then given a Cytosponge screening test.
Study population
Training Cohort. The training cohort was a cross sectional
multicentre survey of epidemiological factors predictive of BE in
unselected patients between the ages of 18–75, attending an upper
gastrointestinal endoscopic examination on clinical grounds
between 2001 and 2004. 2171 patients were recruited from
Addenbrooke’s Hospital, Barking Havering and Redbridge
Hospitals, and University College London Hospitals during the
study period after approval from the local ethics committee.
Informed consent was obtained from each study participant.
Exclusion criteria included those with a prior diagnosis of BE or a
previous gastrointestinal malignancy. Among the 2171 partici-
pants, 252 individuals did not complete the questionnaire and 11
people had missing information on endoscopy results leading to
263 excluded. Furthermore, we excluded 277 participants with
known BE undergoing surveillance and 28 patients with a history
of cancer as their responses to the questionnaire may be biased by
awareness of their health condition. Hence, 1603 were included in
the training cohort for analysis.
Validation Cohort. The validation cohort was obtained from
a prospective study, called BEST2 whose primary aim is to
evaluate the Cytosponge diagnostic device. The study has a case-
control design in which cases are patients with known Barrett’s
oesophagus and controls are unselected patients between the ages
of 18–75, with symptoms of reflux or dyspepsia attending an upper
gastrointestinal endoscopic examination on clinical grounds.
Hence, the control arm is very similar to the training cohort
described above. In total, there were 477 participants recruited
after approval from the local ethics committee. Informed consent
was obtained from each study participant.
Definition of Barrett’s esophagus
There is no uniform consensus regarding the definition of BE.
The American Gastroenterological Association recommends that
IM is required for the diagnosis [31], while the British Society of
Gastroenterology does not require IM[32]. There have also been
variations in the length of columnar lined segment required in
different countries and over time; and it is recognized that with
short lengths the reliability coefficients for diagnostic agreement
diminish considerably [33]. Therefore, in the current study, two
definitions of BE were used. The first one was defined as columnar
lined epithelium of esophagus (CLE) of any length reported in the
endoscopy report with columnar epithelium on biopsy regardless
of whether it was gastric or intestinal in type. The second
definition was stricter to minimize any misclassification, and
comprised a maximal endoscopic length of BE $2 cm with IM
confirmed on histopathological assessment (IM$2 cm). We
reported the maximal length of BE in line with the Prague
classification. All endoscopists were trained in how to identify the
landmarks and the top of the gastric folds was used to identify the
gastroesophageal junction.
Questionnaires
The data collected in the training and validation cohorts was
broadly similar though they used different questionnaires to collect
the information. The questionnaire in the training cohort included
65 questions and was developed based on two validated
questionnaires, the gastro-esophageal reflux questionnaire of 80
items[28] and another 27-item GERD symptom questionnaire
[27]. In the validation cohort, the GERD symptoms were collected
by a questionnaire adapted from the GERD Impact Scale [34].
The last question in the GERD Impact Scale, ‘‘How often did you
take additional medication other than what the physician told you
to take (such as Tums, Rolaids, Maalox)’’ was adapted to ‘‘Are you
taking medication for your stomach symptoms’’. The demographic
information was collected at the endoscopy appointment in a semi-
structured interview. All the information was captured by an
online database specially designed for the study.
Statistical Methods
Fifteen candidate variables which were collected in both cohorts
were used to build the prediction model, including 1) demographic
factors: age, sex, BMI, ethnic group, education, smoking status,
and alcohol consumption; 2) family history: BE and EAC; 3)
symptoms: heartburn, acid reflux, chest pain, upper stomach pain,
and being woken at night by symptoms; 4) medication for
‘‘stomach’’ symptoms. The associations between the fifteen
variables and a diagnosis of BE were tested using the chi-square
test for categorical variables, trend test for ordinal variable and t-
test for continuous variables. Only those reaching the significance
level of 0.05 or borderline significant level of 0.10 were included as
potential predictors for model training. A backward logistic
regression model was developed based on all the potential
predictors to select the final panel for validation. Each predictor
in the panel was weighted based on the coefficients from the
backward logistic regression model in the training cohort. A risk
score was calculated using the weights of each predictor for each
patient in the validation cohort. Receiver operating characteristic
(ROC) curve was created using the risk scores in the validation
A Pre-Screening Tool for Barrett’s Esophagus
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Table 1. Demographic characteristics according to endoscopic BE and pathological BE in the training cohort*.
CLE IM$2 cm
BE Normal P BE Normal P
N 182 1421 69 1534
Age (yrs) 58.1 (12.7) 51.7 (14.2) ,0.001 60.9 (11.9) 52.0 (14.1) ,0.001
BMI (kg/m2) 27.1 (4.2) 26.6 (5.1) 0.21 27.5 (4.5) 26.6 (5.1) 0.16
Ethnic
Caucasian 128 (11.4%) 996 (88.6%) 0.19 51 (4.5%) 1,073 (95.5%) 0.30
Bangladeshi 32 (13.9%) 198 (86.1%) 11 (4.8%) 219 (95.2%)
Other 6 (6.7%) 83 (93.3%) 1 (1.1%) 88 (98.9%)
Sex
Male 118 (15.1%) 665 (84.9%) ,0.001 46 (5.9%) 737 (94.1%) 0.003
Female 62 (7.6%) 756 (92.4%) 23 (2.8%) 795 (97.2%)
Education
High school or less 128 (12.2%) 917 (87.8%) 0.21 50 (4.8%) 995 (95.2%) 0.51
College 29 (11.4%) 225 (88.6%) 10 (3.9%) 244 (96.1%)
University or higher 16 (7.3%) 203 (92.7%) 8 (3.7%) 211 (96.3%)
Other 3 (9.4%) 30 (90.6%) 0 (0%) 33 (100.0%)
Smoking
Never 59 (10.6%) 500 (89.4%) 0.05 18 (3.2%) 541 (96.8%) 0.05
Former 57 (12.9%) 385 (87.1%) 25 (5.7%) 417 (94.3%)
Current 26 (7.5%) 322 (92.5%) 9 (2.6%) 339 (97.4%)
Alcohol drinking
Non-drinker 18 (8.8%) 186 (91.2%) 0.35 9 (4.4%) 195 (95.6%) 0.74
Drinker 127 (11.0%) 1,024 (89.0%) 45 (3.9%) 1,106 (96.1%)
Family history of BE
Yes 3 (16.7%) 15 (83.3%) 0.45 2 (11.1%) 16 (88.9%) 0.18
No 179 (11.3%) 1,406 (88.7%) 67 (4.2%) 1,518 (95.8%)
Family history of EAC
Yes 8 (12.7%) 55 (87.3%) 0.73 2 (3.2%) 61 (96.8%) 1.0
No 174 (11.3%) 1366 (88.7%) 67 (4.4%) 1,473 (95.6%)
Heartburn
Never 25 (8.4%) 271 (91.6%) 0.007{ 9 (3.0%) 287 (97.0%) 0.04{
Sometimes 14 (8.1%) 159 (91.9%) 3 (1.7%) 170 (98.3%)
Often 46 (10.1%) 410 (89.9%) 18 (3.9%) 438 (96.1%)
Daily 60 (14.6%) 351 (85.4%) 23 (5.6%) 388 (94.4%)
Acid flux
Never 37 (9.1%) 371(90.9%) 0.009{ 12 (2.9%) 396 (97.1%) 0.07{
Sometimes 17 (6.3%) 253 (93.7%) 8 (3.0%) 262 (97.0%)
Often 57 (13.1%) 378 (86.9%) 20 (4.6%) 415 (95.4%)
Daily 31 (14.0%) 190 (86.0%) 12 (5.4%) 209 (94.6%)
Chest Pain
Never 70 (13.0%) 467 (87.0%) 0.03{ 29 (5.4%) 508 (94.6%) 0.07{
Mild 31 (9.4%) 299 (90.6%) 10 (3.0%) 320 (97.0%)
Moderate 35 (10.3%) 305 (89.7%) 10 (2.9%) 330 (97.1%)
Severe 8 (6.3%) 120 (93.8%) 4 (3.1%) 124 (96.9%)
Being woken at night by symptoms
No 86 (11.6%) 654 (88.4%) 0.75 32 (4.3%) 708 (95.7%) 0.97
Yes 96 (11.1%) 767 (88.9%) 37 (4.3%) 826 (95.7%)
Abdominal pain
No 59 (16.4%) 301 (83.6%) ,0.001 28 (7.8%) 332 (92.2%) ,0.001
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cohort to evaluate the sensitivity and specificity of the prediction
model.
All the analyses were performed using SPSS version 19.0 (SPSS
Inc, Chicago, IL, USA) and R version 2.15.0.
Results
Demographic factors and GERD symptoms are associated
with presence of BE
Among the 1,603 patients in the training cohort analysis, the
average age of the cohort was 52.4 years, and the male to female
sex ratio was 0.96:1. The prevalence of CLE was 11.4% (182/
1603) whereas the prevalence of IM$2 cm was 4.3% (69/1603).
Among the 113 patents not fulfilling the criteria of IM$2 cm,
there were 95 (84.1%) patents without IM and 18 (15.9%) patients
with IM,2 cm. Table 1 shows the demographic and clinical
characteristics of the study population according to the two
different definitions of BE. The associations of all these factors with
CLE and IM$2 cm were similar, except that the associations with
acid reflux and chest pain for IM$2 cm were borderline
significant (p = 0.07) while both associations were significant for
CLE.
Prediction model for BE
All eight factors that reached the significance level of 0.1 (age,
sex, smoking, heartburn, acid reflux, chest pain, abdominal pain,
medicine for symptoms) in the training cohort were used to build a
statistical model by backward logistic regression. To simplify the
model for clinical usage, we dichotomized the symptoms that have
four categories based on the univariate analysis, including
heartburn (Never & Sometimes vs. Often & Daily), acid reflux
(Never & Sometimes vs. Often & Daily) and chest pain (No chest
pain vs chest pain). Table 2 shows the predictors selected for both
Table 2. The coefficients, weights and odds ratios of selected predictors for BE.
CLE IM$2 cm
b Weight OR (95%CI) b Weight OR (95%CI)
Age (per 1 yr) 0.025 1 1.03 (1.01–1.04) 0.037 1 1.04 (1.01–1.06)
Sex
Female 0 0 Ref 0 0 Ref
Male 0.725 29 2.06 (1.37–3.11) 0.679 18 1.97 (1.03–3.79)
Heartburn*
Never & Sometimes n/a n/a n/a 0 0 Ref
Often & Daily n/a n/a n/a 0.594 16 1.81 (0.87–3.79)
Acid flux*
Never & Sometimes 0 0 Ref n/a n/a n/a
Often & Daily 0.663 27 1.94 (1.28–2.94) n/a n/a n/a
Chest Pain
No 0 0 Ref 0 0 Ref
Yes 20.483 219 0.62 (0.41–0.93) 20.552 215 0.58 (0.30–1.09)
Abdominal pain
No 0 0 Ref 0 0 Ref
Yes 20.579 223 0.56 (0.37–0.85) 21.125 230 0.33 (0.17–0.61)
Anti-reflux medication
No 0 0 Ref 0 0 Ref
Yes 0.784 31 2.19 (1.45–3.32) 1.308 35 3.70 (1.82–7.53)
*n/a: not applicable.
doi:10.1371/journal.pone.0094163.t002
Table 1. Cont.
CLE IM$2 cm
BE Normal P BE Normal P
Yes 85 (8.7%) 895 (91.3%) 25 (2.6%) 955 (97.4%)
Anti-reflux medication
No 47 (7.3%) 597 (92.7%) ,0.001 14 (2.2%) 630 (97.8%) ,0.001
Yes 88 (14.3%) 528 (85.7%) 38 (6.2%) 578 (93.8%)
*Data shown are mean (SD) for continuous variables and number (percentage) for categorical variables
{P for trend test.
doi:10.1371/journal.pone.0094163.t001
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definitions of BE by backward logistic regression models and the
weight for each predictor based on the coefficients of the models.
The odds ratio and 95%CI for each predictor was also reported.
Age, sex, chest pain, abdominal pain and medication for
‘‘stomach’’ symptoms were selected as predictors for both CLE
and IM$2 cm. Heartburn was selected as a predictor for
IM$2 cm only, while acid reflux was selected only for CLE.
Internal validation was carried out based on the weights given in
Table 2. Risk scores for CLE and IM$2 cm were calculated
separately. For example, the CLE risk score of a 60-year male with
symptoms of heartburn, acid reflux, chest pain who has used
medications for ‘‘stomach’’ symptoms is: 6061+29+27219+
31= 128, while the risk score for IM$2 cm for that patient is:
6061+18+16215+35=114. The medians and inter quartile
ranges for the risk scores of CLE and IM$2 cm in the training
cohort were 65 (45–87) and 57 (34–79), respectively. The AUCs
generated using the risk scores were 0.72 (95%CI: 0.67–0.77) for
CLE, and 0.81 (95%CI: 0.76–0.86) for IM$2 cm (Figure 1).
Demographic characteristics of the external validation
cohort
Table 3 shows the summary of the predictors for BE in the
validation cohort. Among the 477 participants in the external
validation cohort, the prevalence of CLE and IM$2 cm were
13.8% (66/477) and 4.4% (21/477), respectively. There were 45
CLE patients not fulfilling the criteria of IM$2 cm, including 26
(57.8%) CLE patients without IM and 19 (42.2%) CLE patients
with IM but having a segment of BE less than 2 cm. The mean age
of the validation cohort was 54.7 years and 45.5% of the patients
were male. There was no significant difference in the prevalence of
CLE and IM$2 cm between the training cohort and the
validation cohort (p = 0.17 and p= 1.0, respectively), while people
in the external validation cohort were older than those in the
training cohort (mean age: 54.7 yrs vs. 52.4 yrs, p = 0.002). The
sex ratio of male to female in the validation cohort was 0.83:1,
which is not significantly different from the training cohort
(p = 0.18).
External validation of the eight factor panel
The risk scores for both CLE and IM$2 cm were then
calculated by the weights of the predictors in each panel for CLE
and IM$2 cm from the training cohort. The median and inter
quartile ranges for CLE and IM$2 cm were 67 (46–89.5) and 60
(40–79.5), respectively. Figure 2 shows the ROC curves for the two
BE definitions in the validation cohort. The AUCs were 0.61
Table 3. Summary of the predictors for BE in the external
validation cohort*.
External validation cohort
N 477
CLE 67 (14.0%)
IM$2 cm 21 (4.4%)
Age (yrs) 54.7 (14.7)
Sex(male) 217 (45.5%)
Heartburn
Never & Sometimes 314 (66.4%)
Often & Daily 159 (33.6%)
Acid reflux
Never & Sometimes 329 (69.6%)
Often & Daily 144 (30.4%)
Chest Pain
No 184 (38.9%)
Yes 289 (61.1%)
Abdominal pain
No 159 (33.6%)
Yes 314 (66.4%)
Anti-reflux medication
No 188 (39.7%)
Yes 285 (60.3%)
*Data shown are mean (SD) for continuous variables and number (percentage)
for categorical variables.
doi:10.1371/journal.pone.0094163.t003
Figure 1. ROC curve for a) endoscopically visible CLE of any
length independent of histology (AUC: 0.72), b) segment
containing IM$2 cm (AUC: 0.81) in the training cohort
(N=1603). ROCs curve were developed using the risk scores which
are calculated using the weights of different predictors. The weights
were developed based on the coefficients of predictors in the backward
logistic regression model in the training cohort.
doi:10.1371/journal.pone.0094163.g001
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(95%CI: 0.54–0.68) and 0.64 (95%CI: 0.52–0.77) for CLE and
IM$2 cm, respectively. We used 2000 bootstraps to estimate the
specificities of the ROCs in the validation cohort at sensitivities of
90% and 95%. The median specificities were 21% (95%CI: 15%–
37%) and 22% (95%CI: 2%–53%) for CLE and IM$2 cm at
sensitivity of 90%, respectively, while at sensitivity of 95%, the
median specificities were 17% (95%CI: 11%–25%) and 19% (2%–
41%), respectively.
Discussion
In the current study, we set out to develop a pre-screening tool
to improve the cost-effectiveness and logistics of screening for BE.
We did this by evaluating the associations of demographic factors,
symptoms and medication with the presence of BE in a
prospective cohort study including 1603 patients. Two different
panels were developed in the training cohort for endoscopically
identified CLE (any length and with or without IM) and
IM$2 cm, respectively. The panel for CLE included age, sex,
chest pain, abdominal pain, medication for ‘‘stomach’’ symptoms
and acid reflux, while the panel for IM$2 cm included the same
factors except acid reflux was replaced by heartburn and the
weightings given to these factors varied as summarized in Table 2.
We then validated the two panels in another independent cohort
comprising 477 patients and found that both panels have a fair
diagnostic accuracy.
Previous studies have reported a number of risk factors
associated with BE, including age [9,10], gender [9,11,12],
ethnicity [13–15], GERD [10,16,17], smoking[18–20] and central
obesity [9,21,22]. The results in the current study were consistent
with previous studies except for smoking, ethnicity and central
obesity. Although smoking was significantly associated with BE in
the univariate analysis, the association was no longer significant
after controlling for other variables and thus the association is very
likely confounded by other factors. Since the current study did not
collect the information on waist and hip circumference, we cannot
evaluate the association with central obesity. We did not find a
significant association with ethnicity. The possible explanation is
that there were only a small percentage of patients with self-
reported ethnicities other than Caucasian and Bangladeshi. In this
study, we found Bangladeshi patients living in the UK have a
similar prevalence of BE compared to Caucasian patients, which
was about twice as much as the prevalence seen in other ethnic
patients. To our best knowledge, this is the first study reporting a
high prevalence of BE in Bangladeshi patients.
Table S1 shows a summary of four previous studies which
aimed to use a questionnaire to predict BE [27–30]. Although the
target populations, BE definitions and hence the prevalence of BE
were different between the current study and previous studies, the
prediction panel was similar, and included a combination of
demographic factors, GERD symptoms and anti-reflux medica-
tion. In addition, the accuracy of the prediction panels in the
training cohort of our current study is similar to the previous
studies, in which the AUCs were between 0.70–0.76 (Table S1).
However, neither Gerson et al. nor Locke et al. nor Rubenstein et al.
validated their panel in another independent cohort. It is likely
that the diagnostic accuracy will drop significantly in validation
cohorts because of over-fitting of the model in the training dataset.
Although Thrift et al. validated their panel in another independent
study, both the training and the validation datasets in their study
used a retrospective case-control design. Moreover, in this study,
all patients were interviewed after the endoscopy examination,
which may have introduced recall bias [29]. The strengths of the
current study are that we developed the prediction panels based on
a prospective unselected cohort referred for endoscopy, and
further validated the panels in another similar prospective cohort
referred for endoscopy. In addition, we collected all the
information before the endoscopy in both training and validation
cohorts.
Whether or not to screen for BE has been a subject of intense
debate. Currently, both the British Society of Gastroenterology
(BSG) and the American Gastroenterological Association (AGA)
guidelines recommend against routine endoscopic screening of
individuals with GERD due to the low incidence of esophageal
cancer in BE and the high cost and side effect of endoscopy
[31,32,35]. In addition, several studies have concluded that
identification and surveillance for BE patients has minimal public
health impact on esophageal adenocarcinoma, and this is at least
Figure 2. ROC curve for a) endoscopically visible CLE of any
length independent of histology (AUC: 0.61), b) segment
containing IM$2 cm (AUC: 0.64) in the external validation
cohort (N=477). ROCs curve were developed using the risk scores
which are calculated by the weights of different predictors. The weights
were developed based on the coefficients of predictors in the backward
logistic regression model in the training cohort.
doi:10.1371/journal.pone.0094163.g002
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in part because the vast majority of esophageal adenocarcinomas
are diagnosed in patients who did not have a prior diagnosis of BE
[36,37]. On the other hand, surveillance-detected cancers and
cancers with a previous diagnosis of BE are associated with earlier
stage and have a better prognosis compared to those presenting de
novo, although evidence from randomized trials is lacking
[35,38,39]. It is likely that a large group of BE patients are
undiagnosed because they do not meet the indications for
endoscopy. Furthermore, the possibility of using lower cost non-
endoscopic screening tools [26] and the advent of endoscopic
techniques to treat early cancer means that the time is ripe to
reconsider screening [40].
Whilst far from perfect the panels developed in our study have a
similar accuracy to those reported in previous studies (Table S1).
As a pre-screening tool, the panels are low cost and easy to
perform. Most importantly, the panels can identify 95% of BE
patients for further investigation while saving unnecessary
screening for around 20% of patients who at endoscopy are
subsequently found not to have BE. Figure S1 shows a flowchart
outlining the proposed use of the panel as a pre-screening tool
before screening. To give some idea of the implications of such a
pre-screening tool, we built cost-effective models based on the
following assumptions: 1) the population size is 100,000; 2) the
starting age for screening is 40 years and life expectancy is 85
years; 3) surveillance is conducted every three years in BE patients
diagnosed by screening [31]; and 4) the progression rate from BE
to high grade dysplasia (HGD) or EAC is taken to be 0.38% per
year [41]. Table S2 shows the comparison of the number of
procedures required before and after the introduction of the panels
in populations with a hypothetical prevalence of BE of 1%, 5%
and 10%. For example, in the population with the prevalence of
BE of 1%, 100,000 screening tests and another 14,229 surveillance
tests are needed to diagnose all 157 EACs predicted to occur in the
45 years of follow-up; in contrast by using our panels as a pre-
screening tool, only 80,150 screening tests and another 13,584
surveillance tests are needed to detect 95% EAC patients (8
patients missed). The pre-screening tool can be designed as an
online tool and the cost of the pre-screening process will be
significantly less than the cost of saved procedures. Hence, at 95%
sensitivity the introduction of the panel saves 20,565 tests per
100,000 screening population overall or 101 tests to detect one
EAC patient. We believe that our panel can be further improved
by including central adiposity measurement since it has been
reported as a risk factor of BE in several other studies [30,42,43].
In addition, Thrift et al. reported that biomarkers, such as
circulating serum levels of inflammatory cytokines and leptin can
improve the model performance in predicting BE [42]. However,
we believe that it may be impractical to add biomarkers to a pre-
screening panel given the cost and logistical considerations for
biomarker measurement.
There are several limitations to the current study. First of all, the
questionnaire used in the training cohort was developed based on
two previous published studies and was not independently
validated, but the effect on our study results was limited as the
previous studies have validated the questionnaires. Secondly, in
the current study, we used a slightly different questionnaire in the
training cohort compared with the validation cohort. However, to
minimize any effect on the validation and simplify the clinical
usage of the panels, we dichotomized the symptoms.
In conclusion, we have demonstrated that prediction models
which incorporate demographics, symptoms and medication for
‘‘stomach’’ symptoms can predict the prevalence of BE with high
sensitivity and fair specificity to a range within the intended aims
of this study. Hence, the models have the potential to be used as a
pre-screening tool to avoid around 20% of patients having
unnecessary investigations and thus pre-select a more relevant
population of patients to have a diagnostic test for BE such as
trans-nasal endoscopy or the Cytosponge.
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